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Abstract
Background: The SARS outbreak in 2003 provides a unique opportunity for the study of human
responses to a novel virus. We have previously reported that dendritic cells (DCs) might be
involved in the immune escape mechanisms for SARS-CoV. In this study, we focussed on the gene
expression of toll-like receptors (TLRs), chemokine receptors (CCRs) and death receptor ligands
in SARS-CoV infected DCs. We also compared adult and cord blood (CB) DCs to find a possible
explanation for the age-dependent severity of SARS.
Results: Our results demonstrates that SARS-CoV did not modulate TLR-1 to TLR-10 gene
expression but significantly induced the expression of CCR-1, CCR-3, and CCR-5. There was also
strong induction of TNF-related apoptosis-inducing ligand (TRAIL), but not Fas ligand gene
expression in SARS-CoV infected DCs. Interestingly, the expressions of most genes studied were
higher in CB DCs than adult DCs.
Conclusion: The upregulation of chemokines and CCRs may facilitate DC migration from the
infection site to the lymph nodes, whereas the increase of TRAIL may induce lymphocyte apoptosis.
These findings may explain the increased lung infiltrations and lymphoid depletion in SARS patients.
Further explorations of the biological significance of these findings are warranted.
Background
The SARS outbreak in 2003 provides a unique opportu-
nity for the study of human response to a novel virus. The
etiological agent was identified to be a coronavirus (CoV)
originating from an animal reservoir [1,2]. Clinically,
patients presented with an atypical pneumonia followed
by diffuse alveolar damage, with mortality up to 52% in
patients over 65 years old. Interestingly, the disease pres-
entations of SARS were less severe in children than adults,
and none of the infected children (< 12 years old) died of
SARS [3,4]. Evidences in the literature, including ours,
support the role of immune evasion in the severity and
immunopathology of SARS (Reviewed by [5-7]), and we
further suggested that the developmental status of the
host immune system may be responsible for the age-
dependence of disease severity in SARS.
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BMC Immunology 2009, 10:35 http://www.biomedcentral.com/1471-2172/10/35In our previous report [8], we have demonstrated that
dendritic cells (DCs), the key antigen presenting cells with
crucial role in anti-viral immune responses, might also be
involved in the immune escape mechanisms for SARS-
CoV. There was entry and incomplete replication of SARS-
CoV in DCs but there was no production of infectious
virus released into the culture medium [8]. SARS-CoV
infection did not lead to DCs apoptosis or DC matura-
tion.
Interestingly, the SARS-CoV infected DCs showed low
expression of antiviral cytokines (IFN-α, IFN-β, IFN-γ and
IL-12p40), moderate upregulation of proinflammatory
cytokines (TNF-α and IL-6) but significant upregulation
of inflammatory chemokines (macrophage inflammatory
protein (MIP)-1α/CCL3, regulated upon activation, nor-
mal T cell expressed and secreted (RANTES)/CCL-5, inter-
feron-inducible protein of 10 kD (IP-10)/CXCL10 and
monocyte chemotactic protein (MCP)-1/CCL2. We postu-
lated that this lack of antiviral cytokine response against a
background of intense chemokine upregulation could
represent a mechanism of immune evasion by SARS-CoV.
In the current study, we focused on the receptor responses
in SARS-CoV infected DCs and compared adult and cord
blood (CB) DCs to establish possible explanation for the
age dependent severity of SARS. DCs express a wide range
of receptors for the recognition of conserved pathogen
patterns as well as the induction of subsequent immune
responses. Some Toll like receptors (TLRs) are expressed
on the cell surface (TLR-1, TLR-2, TLR-4, TLR-5, TLR-6,
TLR-10) while some are located within intracellular com-
partments (TLR-3, TLR-7, TLR-8, TLR-9) [9]. They are dif-
ferentially expressed in different DC subsets and are
modulated in response to a variety of stimuli [10,11].
Viral proteins may bind to TLR-2 or TLR-4, single stranded
RNA binds to TLR-7 and TLR-8, and double stranded RNA
binds TLR-3 while viral DNA binds to TLR-9. The binding
of ligands to TLRs may trigger downstream signaling path-
ways that are involved in both the cytokine release during
the primary induction of inflammation and secondary
activation of anti-inflammatory mechanisms [12]. Cross
talks between TLRs are common and the formation of TLR
heterodimers allows a higher level of complexity in lig-
and-receptor binding and subsequent signaling.
The migration of DCs from peripheral tissues to lymph
nodes is essential for antigen presentation and triggering
of adaptive immune responses. The trafficking of DCs is
regulated by chemokines in their microenvironment and
their expression of chemokine receptors (CCRs). Differen-
tial expressions of CCRs are observed during DC matura-
tion [13,14] and some viruses, such as herpes simplex
virus (HSV), can block CCR expressions on DCs to alter
their migratory properties [15]. There are redundancies in
the chemokines and CCRs interactions as many different
ligands bind the same receptor and many receptors bind
the same ligand. For example, RANTES binds to CCR-1,
CCR-3 and CCR-5, while MIP-1α also binds to CCR-1 and
CCR-5 [16]. We determined if the expression of these
receptors on DCs are altered by SARS-CoV and contribute
to autocrine regulation of DC migration.
Death receptors (DRs) and their ligands also play impor-
tant roles in innate and adaptive immune responses by
regulating cell death and survival [17]. Well-characterized
death receptor ligands (DRLs) include tumor necrosis fac-
tor (TNF)-α, FasL and TNF-related apoptosis-inducing lig-
and (TRAIL/Apo2L). Recently, several viruses, including
measles virus [18], human immunodeficiency virus (HIV)
[19], cytomegalovirus (CMV) [20], and herpes simplex
virus (HSV) [21], were shown to induce TRAIL expression
on DCs. These "killer DCs" may be involved in the killing
of virus-infected cells or bystander lymphocytes and natu-
ral killer cells. In view of the lymphopenia observed in
SARS patient, we determine if DRLs expression on DCs is
modulated by SARS-CoV.
This study provides evidence that SARS-CoV does not alter
the TLRs, but modulates CCRs and DLRs expression in
DCs; and further suggests possible mechanisms of
immune escape and amplification of immunopathology
in SARS.
Results
SARS-CoV did not stimulate the gene expression of TLRs in 
immature DCs
Gene expression of extracellular TLRs (TLR-1, TLR-2, TLR-
4, TLR-5, TLR-6) in DCs are summarised in Fig. 1. There
was a low (<50 copies/per 104 β-actin), but significant
upregulation of TLR-1 and TLR-2 in SARS-CoV infected
adult DCs at 3 h post infection. A similar trend was
observed in CB DCs but the difference did not reach sta-
tistical significance. In CB DCs, the basal gene expressions
of TLR-1, TLR-2, and TLR-5 and the SARS-CoV induced
TLR-2 and TLR-4 expression were significantly higher than
that in adult DCs (Table 1). No expression of TLR-10 was
detected in either adult or CB DCs (data not shown).
Gene expression of intracellular TLRs (TLR-3, TLR-7, TLR-
8, TLR-9) in DCs are summarised in Fig. 2. In adult DCs,
the expression was low (average in range of 0 – 20 copies
per 104 β-actin). The expression of TLR-3, TLR-7 and TLR-
9 were also low in CB DCs (average in range of 0 – 20 cop-
ies per 104 β-actin). The basal gene expression of TLR-8
was high in CB DCs and the expression was nearly dou-
bled after SARS-CoV infection at both 3 h and 9 h post
infection. However, due to sample variations the differ-
ence between mock and SARS-CoV infected CB DCs was
not statistically significant.Page 2 of 12
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Extracellular Toll-like receptors gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCRFigur  1
Extracellular Toll-like receptors gene expression in SARS-CoV infected human immature DCs by quantitative 
RT-PCR. Toll-like receptor (TLR)-1, TLR-2, TLR-4, TLR-5, TLR-6 and TLR-10 primarily expressed on cell surface. Their 
mRNA concentrations in adult (a) and CB (b) immature DCs were assayed at 3 h and 9 h after infection with SARS-CoV (MOI 
= 1). Mock infected cells were included as negative control. The concentrations were normalised to those of β-actin mRNA in 
the corresponding sample. In SARS-CoV infected adult DCs, significant upregulation of TLR-1 and TLR-2 at 3 h after infection 
was detected. The basal levels of extracellular TLRs gene expressions in CB DCs were high and no significant upregulation was 
detected after infection with SARS-CoV. Data are shown as mean ± SEM (adult n = 7; CB n = 5). The expression of TLR-10 
was <1 copy per 104 β-actin genes (Data not shown).
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BMC Immunology 2009, 10:35 http://www.biomedcentral.com/1471-2172/10/35SARS-CoV stimulated moderate expression of CCR genes 
in immature DCs
Comparing the mock and SARS-CoV infected adult DCs,
there was moderate induction of CCR-1, CCR-3, CCR-5
and CCR-7 at both 3 h and 9 h post infection (Fig. 3) but
only that observed for CCR-1 and CCR-5 reached statisti-
cal significance. It is important to note that at 3 h post
infection, the CCR-3 expression in mock infected adult
DCs was very low (average <1 copies per 104 β-actin) but
it increased to 183.91 ± 128.35 copies per 104 β-actin after
SARS-CoV infection. In SARS-CoV infected CB DCs, a
strong and significant upregulation was observed for
CCR-3 at both 3 h and 9 h post infection. In general, the
expressions of these CCRs in CB DCs were significantly
higher than in adult DCs (Table 1).
SARS-CoV upregulated TRAIL but not FasL gene 
expression in immature DCs
We also assayed the expression of DRLs in SARS-CoV
infected DCs as they may have an impact on the killing of
bystanding immune cells. The gene expressions of FasL
and TRAIL in DCs were summarised in Fig. 4. In both
adult and CB DCs, FasL gene expression was low (~0–40
copies per 104 β-actin) and there was a slight and insignif-
icant induction by SARS-CoV. In the contrary, a strong
induction of TRAIL gene expression was observed in
SARS-CoV infected DCs at both 3 h and 9 h post infection.
The upregulated TRAIL expression in CB DCs were signif-
icantly higher than that in adult DCs (Table 1).
Discussion
Dendritic cells are professional antigen presenting cells
that play an important role as sentinels at the infection
site by interacting directly with pathogens. Some patho-
gens hijack different parts of the immune pathways
involving DCs to enhance their survival. In the present
study, we demonstrate that SARS-CoV does not have sig-
nificant effect on the expression of TLRs on adult or CB
DCs (Figs. 1 &2). However, there was significant upregu-
lation of CCR-1 and CCR5 in SARS-CoV infected adult
DCs and CCR-3 in SARS-CoV infected CB DCs which may
be related to the autocrine regulation of DC migration
(Fig. 3). Moreover, we demonstrate a significant upregula-
tion of TRAIL on both adult and CB DCs (Fig. 4). We
hypothesize that the upregulation of chemokine receptors
may facilitate the autocrine mobilisation of DCs away
from the infection sites and the upregulation of death
receptor liganads may result in apoptosis of other
immune cells, leading to immunosuppression and lym-
phopenia.
TLRs are expressed on many cell types and their expres-
sion on different DC subsets have been characterised. Vis-
intin et al. [22] measured TLR expression on immature
human DCs by monoclonal antibodies binding, but the
expression was very low, corresponding to a few hundred
molecules or less in immature DCs. Subsequent studies of
TLRs expressions were based on comparing RNA expres-
sion quantitatively and some reports for immature DCs
have been controversial. Our detection of TLR-1 to TLR-9
expressions in mock infected adult DCs were consistent
with that reported by Jarrossay et al. [10] and the low level
of TLR-10 was similar to that reported by Kadowaki et al.
[11].
Viruses may subvert the TLR response to evade the host
defense by: (a) producting specific viral particles that
block TLR function, (b) blocking TLR recognition and (c)
stimulating viral replication through TLRs [23]. Viral
infections, by RSV or influenza A, have been shown to
Table 1: CB immature DCs expressed significantly higher level of 
some receptor genes than adult immature DCs**
3 h p.i. 9 h p.i.
MOCK SARS-CoV MOCK SARS-CoV
TLR-1 p = 0.02 - - -
TLR-2 p = 0.003 p = 0.003 p = 0.003 p = 0.003
TLR-3 - - - -
TLR-4 - p = 0.03 - -
TLR-5 p = 0.004 - p = 0.04 -
TLR-6 - - - -
TLR-7 p = 0.04 - - -
TLR-8 - - - -
TLR-9 - - - -
CCR-1 - p = 0.02 - p = 0.005
CCR-3 - - - -
CCR-5 - - - p = 0.02
CCR-7 p = 0.02 p = 0.01 - p = 0.03
FasL - - - -
TRAIL - p = 0.005 - p = 0.01
**Adult DCs (n = 7)
CB DCs (n = 5)
TLR, toll-like receptor; CCR, chemokine receptor; FasL, Fas ligand; 
TRAIL, Tumor necrosis factor (TNF)-related apoptosis-inducing 
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Intracellular Toll-like receptors gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCRFigur  2
Intracellular Toll-like receptors gene expression in SARS-CoV infected human immature DCs by quantitative 
RT-PCR. Toll-like receptor (TLR)-3, TLR-7, TLR-8 and TLR-9 primarily expressed intracellularly. Their mRNA concentrations 
in adult (a) and CB (b) immature DCs were assayed at 3 h and 9 h after infection with SARS-CoV (MOI = 1). Mock infected 
cells were included as negative control. The concentrations were normalised to those of β-actin mRNA in the corresponding 
sample. In SARS-CoV infected adult DCs, low but significant upregulation of TLR-7 was detected at 9 h after infection. The 
basal levels of intracellular TLR-8 gene expression in CB DCs was very high and no significant upregulation was detected after 
infection with SARS-CoV. Data are shown as mean ± SEM (adult n = 7; CB n = 5).
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Chemokine receptors gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCRFigure 3
Chemokine receptors gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCR. 
Chemokine receptors, CCR-1, CCR-3, CCR-5, CCR-7, mRNA concentrations in adult (a) and CB (b) immature DCs were 
assayed at 3 h and 9 h after infection with SARS-CoV (MOI = 1). Mock infected cells were included as negative control. The 
concentrations were normalised to those of β-actin mRNA in the corresponding sample. In SARS-CoV infected adult DCs, sig-
nificant upregulations of CCR-1, CCR-3 and CCR-5 were detected. In the CBDCs, only upregulation of CCR-3 was detected. 
Data are shown as mean ± SEM (adult n = 7; CB n = 5).
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Death Receptor Ligand gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCRFigure 4
Death Receptor Ligand gene expression in SARS-CoV infected human immature DCs by quantitative RT-PCR. 
Death receptor ligands, FasL and TRAIL, mRNA concentrations in adult (a) and CB (b) immature DCs were assayed at 3 h and 
9 h after infection with SARS-CoV (MOI = 1). Mock infected cells were included as negative control. The concentrations were 
normalised to those of β-actin mRNA in the corresponding sample. In both SARS-CoV infected adult DCs and CB DCs, signif-
icant upregulation of FasL mRNA was not detected. However, there was significant upregulation of TRAIL gene expression. 
Data are shown as mean ± SEM (adult n = 7; CB n = 5).
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BMC Immunology 2009, 10:35 http://www.biomedcentral.com/1471-2172/10/35upregulate TLR-3 and TLR-4 expression in host airway epi-
thelial cells, leading to increased signalling activity and
proinflammatory cytokine production [23]. More
recently, TLR-4 was shown to be upregulated in mice with
acid-induced or inactivated avian influenza-induced lung
injuries; and TLR-4 deficient mice showed less severe
acute lung injuries to these challenges [24]. We, therefore,
determined if SARS-CoV may modulate the TLRs expres-
sion on DCs. In this study, there was no induction nor
suppression of TLRs in SARS-CoV infected DCs (Figs. 1
&2). The variations between samples were high, but the
expression levels of some extracellular TLRs (TLR-1, TLR-
2, TLR-4, TLR-5) and some intracellular TLRs (TLR-7, TLR-
8) in CB DCs were higher than that in adult DCs (Table
1). Further investigation is needed to determine if the
expression is responsible for the slightly higher Type I
inferferon expression reported in CB DCs [8] and to iden-
tify any correlation with less severe SARS in children.
Interestingly, impaired immune responses to TLR-3 and
TLR-4 ligands have been reported in CB DCs [25].
The majority of TLR research is focussed on the down-
stream signalling pathways triggered by the binding of
specific ligands to TLRs. Activation of TLRs induce signal-
ling cascades which activate transcription factors and gene
expression for anti-inflammatory responses [9]. The iden-
tification of such ligands may have therapeutic applica-
tions for the treatment of SARS. In a recent study on the
control of coronavirus infection by plasmocytoid DCs
(pDCs), it was demonstrated that mouse hepatitis virus
(MHV) induces Type I IFN response and the recognition
of MHV is mediated by TLR7 [26]. The authors demon-
strated that SARS-CoV also induced a strong Type I inter-
feron response in human pDCs and proposed that TLR7
may play a similar role in SARS-CoV infection. Another
group developed a recombinant mouse-adapted SARS-
CoV (rMA15) that was lethal in BALB/c mice and demon-
strated that MyD88 played an important role in SARS-CoV
pathogenesis [27]. Both groups suggested the involve-
ment of TLR7/MyD88/IFNα dependent signaling and fur-
ther exploration is needed to determine if TLR7 agonist
may elicit potent antiviral effects against SARS-CoV infec-
tion.
To date, approximately 50 chemokines and 20 CCRs have
been identified in humans [16] and they play important
roles in inflammation and infectious diseases [28]. In our
previous study, there was significant increase in the
inflammatory chemokines (MIP 1α, RANTES, IP-10 and
MCP-1) in SARS-infected DCs [8]. In addition, we have
shown that SARS patients who have inherited the high-
production gene allele of RANTES have more deaths [29].
In this study, we determined whether the expressions of
representative CCRs (CCR1, CCR-3, CCR-5 and CCR-7)
are also upregulated by SARS. Indeed, there was signifi-
cant induction of CCR-1, CCR-3 and CCR-5 mRNA
expression in SARS-CoV infected DCs (Fig. 3) suggesting
the possibility of a autocrine loop in facilitating the traf-
ficking of DCs. Therefore, further investigation into thera-
peutic strategies which aim at reducing chemokine and
CCRs expresssion are warranted.
Among the CCRs studied, the upregulation of CCR-3 is
the strongest (Fig. 3). It has been reported that the expres-
sion of CCR-3, unlike CCR-5 and CCR-7, are independent
of the maturation status of DCs [13,14]. Further investiga-
tion is needed to determine which mechanism is involved
in CCR-3 upregulation. In addition to cell trafficking,
CCR-3 has also been reported to function as a death recep-
tor on B cells [30]. Whether CCR-3 expression is related to
the characteristic antibody responses in SARS and the
alternative function of CCRs on SARS-CoV infected DCs
will need to be explored further.
CCR-7 has been identified as a key molecule for the estab-
lishment of central and peripheral tolerance. It is strongly
upregulated in herpesvirus infected T cells [31], EBV
infected B cells [32] and mature DCs [14]. In addition,
microarray analysis of PBMC infected with SARS-CoV
have shown an upregulation of CCR7 [33]. In this study,
we only detected a slight but insignificant change in CCR-
7 expression in adult SARS-CoV infected DCs (Fig. 3). This
observation is consistent with previous findings that
SARS-CoV did not stimulate DC maturation [8,34]. How-
ever, this is in contrary to observations made by others
[35,36]. We speculate as these immature DCs migrate to
the lymph nodes, they may act as regulatory DCs which
are less effective for the activation of allogeneic CD4+ T
cells than normal DCs [37] or they may drive the develop-
ment of regulatory T cells [38]. These SARS-CoV-driven
regulatory immature DCs may facilitate the immune eva-
sion of SARS-CoV [39].
Interestingly, we detected significantly higher levels of
chemokines and CCRs genes in CB DCs than in adults
DCs. Based on the function of chemokines on cell traffick-
ing, more severe infiltration of cells to the lungs would be
expected in children. On the contrary, SARS was less
severe in children than adults [3,4]. The age-dependency
of disease severity in SARS merits further studies to eluci-
date the underlying mechanisms. The development of
animal models for SARS has been difficult because rele-
vant signs of clinical illness and death cannot be repro-
ducible in most animal models [40]. Recently, aged BALB/
c mice have shown to develop more severe disease after
SARS infection [41] and have lower vaccine efficacy than
young mice [42]. The comparison of SARS-CoV infected
senescent mice with adult mice can be extended to
younger mice and knock out models for the study of age-
dependency in the pathogenesis of SARS. A recent studyPage 8 of 12
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BMC Immunology 2009, 10:35 http://www.biomedcentral.com/1471-2172/10/35has shown that mice deficient in either CCR1, CCR2 or
CCR5 exhibited more prominent airway epithelial cell
apoptosis and more severe lung pathology. This suggests
that CCRs may be playing different roles at the site of
infection and in the trafficking of immune cells [27].
Using real time quantitative assay, we have shown signif-
icant upregulation of TRAIL gene expression in avian
influenza (H5N1) infected macrophages [43]. Similarly,
SARS-CoV infected DC also showed a "killer DC' pheno-
type with high expression of TRAIL (Fig. 4). Comparing
the two studies, the level of TRAIL expression in SARS-
CoV infected adult DCs (~300 copies/104 β actin genes)
was lower than that in H5N1 infected adult macrophages
(~1800 copies/104 β actin genes). TRAIL expression in
SARS-CoV infected CB DCs was the highest (~5000 cop-
ies/104 β actin genes). Further investigation is needed to
confirm the cytotoxic function of SARS-CoV infected DCs
on immune cells. Based on the possible DC migration
induced by chemokines and the role of TRAIL in inducing
lymphocyte apoptosis, our findings may explain the white
pulp atrophy in the spleen and lymphoid depletion in
lymph nodes of SARS patients. The mechanism involved
in children may be more complicated and it is important
to determine if the CB DCs are functionally immature in
spite of the high expression of chemokines, CCRs and
TRAIL. More recently, TRAIL expression is also reported to
be upregulated after the binding of HIV to TLR-7 [44] or
activation of TLR-8 [45]. Hence the high TRAIL expression
in SARS-infected CB DCs may also be related to their TLR-
8 expression.
Conclusion
This study has characterized important receptor responses
of DCs to SARS-CoV. The suggested mechanisms need to
be substantiated by further research involving a larger
sample size for different pathways as pathogens may have
multiple ways to modify the physiology of DCs to their
advantage.
Methods
Samples
Adult blood samples were from the white cell fraction of
blood donated to the Hong Kong Red Cross by normal
healthy volunteers. Human umbilical cord blood (CB)
samples were collected from the placenta of normal full-
term uncomplicated pregnancies. Informed consent was
obtained from the mothers prior to delivery. The protocol
was approved by the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong
West Cluster [EC1473-00].
Cell separation
Blood mononuclear cells were isolated from whole blood
by centrifugation, using Ficoll-Hypaque gradients (Phar-
macia Biotech, Uppsala, Sweden), washed, and labeled
with immunomagnetic antibodies. Positive selection was
performed according to manufacturer's specification
(Miltenyi Biotec, Bergisch Gladbach, Germany) as in pre-
vious experiments [8]. Isolated CD14+ monocytes from
the positive fraction were resuspended in RPMI 1640, sup-
plemented with 50 IU/ml penicillin and 50 μg/ml strep-
tomycin and 10% fetal bovine serum (Invitrogen, Grand
Island, USA). Cell viability, as measured by trypan blue
exclusion, was more than 95%. The purity of the isolated
cells as measured by flow cytometry was consistantly
between 90% to 95%.
Generation of DCs in vitro
CD14+ monocytes were cultured in the presence of IL-4
(10 ng/ml; R&D, Minneapolis, USA) and GM-CSF (50 ng/
ml; R&D, Minneapolis, USA) for 7 days at 37°C in a
humidified atmosphere containing 5% CO2 as in our pre-
vious study [8]. The cultures were fed with fresh medium
and cytokines on Day 3 and cell differentiation was mon-
itored by light microscopy. On Day 5, DCs were har-
vested, centrifuged, washed and adjusted to 1 × 106 cells/
mL before virus infection.
Virus preparation, titration and infection
Laboratory procedures involving live viruses was per-
formed in biosafety level-3 containment. SARS-CoV,
strain HKU-39849 [1] was cultured in fetal rhesus kidney-
4 (FRhK-4) cells. The cell culture supernatant was har-
vested, centrifuged to remove cell fragments, aliquoted
and kept frozen at -70°C. SARS-CoV titre of the stock virus
was determined by infection of FRhK-4 cells. Cytopathic
changes on FRhK-4 cells was monitored every day up to 4
days and virus titre expressed as tissue culture infective
dose (TCID50).
Cells were inoculated by SARS-CoV at a multiplicity of
infection (MOI) of 1. The virus was allowed to be
adsorbed for 1 hour at 37°C and unbound virus was
washed off by excess volume of PBS (time = 0 h post infec-
tion). Mock infected cells were treated in parallel, except
that virus was not added.
Quantification of RNA expression by real-time 
quantitative PCR
Total RNA was extracted from ~1.5 × 105 cells harvested at
3 h and 9 h post infection by TRIzol Reagent (Invitrogen
Life Technologies, USA). In later experiments, QiaShred-
der columns (Qiagen, Hilden, Germany) were used to
ensure adequate homogenisation and RNA was extracted
by the RNeasy Mini Kit (Qiagen, Hilden, Germany).
Reverse transcription was performed on the DNase-
treated total RNA using oligo (dT) primers and Super-
script II reverse transcriptase (Invitrogen Life Technolo-
gies, USA) according to the manufacturer'sPage 9 of 12
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Table 2: PCR primers and probes
Genes Sequences Sizes (bp)
TLR-1 (F) 5' CAG TGT CTG GTA CAC GCA TGG T 3' 105
(P) 5' (FAM) CAC ATG CTT TGC CAT CCA AAA TTA G (TARMA) 3'
(R) 5' TTT CAA AAA CCG TGT CTG TTA AGA GA 3'
TLR-2 (F) 5' TGT GAA GAG TGA GTG GTG CAA GT 3' 78
(P) 5' (FAM) TGA ACT GGA CTT CTC CCA TTT CCG TCT TT (TARMA) 3'
(R) 5' ATG GCA GCA TCA TTG TTC TCA T 3'
TLR-3 (F) 5' CCT GGT TTG TTA ATT GGA TTA ACG A 3' 82
(P) 5' (FAM) CAT ACC AAC ATC CCT GAG CT (MGB) 3'
(R) 5' TGA GGT GGA GTG TTG CAA AGG 3'
TLR-4 (F) 5' CAC TCG ATG TCA TTC CAA AGT TAT TG 3' 88
(P) 5' (FAM) TAC TAA GTA ATG ACT GTC ATG AAA GCA GCA T (TARMA) 3'
(R) 5' AGA GTG CCC CCT TTA AAC AAA TT 3'
TLR-5 (F) 5' TGC CTT GAA GCC TTC AGT TAT G 3' 77
(P) 5' (FAM) CCA GGG CAG GTG CTT ATC TGA CCT TAA CA (TARMA) 3'
(R) 5' CCA ACC ACC ACC ATG ATG AG 3'
TLR-6 (F) 5' GAA GAA GAA CAA CCC TTT AGG ATA GC 3' 88
(P) 5' (FAM) TGC AAC ATC ATG ACC AAA GAC AAA GAA CCT (TARMA) 3'
(R) 5' AGG CAA ACA AAA TGG AAG CTT 3'
TLR-7 (F) 5' TTA CCT GGA TGG AAA CCA GCT AC 3' 72
(P) 5' (FAM) AGA TAC CGC AGG GCC TCC CGC (TARMA) 3'
(R) 5' TCA AGG CTG AGA AGC TGT AAG CTA G 3'
TLR-8 (F) 5' AGC GGA TCT GTA AGA GCT CCA TC 3' 107
(P) 5' (FAM) CCT GAC AAC CCG AAG GCA GAA GGC (TARMA) 3'
(R) 5' CCG TGA ATC ATT TTC AGT CAA GAC 3'
TLR-9 (F) 5' GCA GTC AAT GGC TCC CAG TTC 3' 116
(P) 5' (FAM) CCC ACA ATA AGC T (MGB) 3'
(R) 5' GCG GTA GCT CCG TGA ATG AGT G 3'
TLR-10 (F) 5' TTA TGA CAG CAG AGG GTG ATG C 3' 152
(P) 5' (FAM) TTG ACC CCA GCC ACA ACG ACA CTG (TARMA) 3'
(R) 5' CTG GAG TTG AAA AAG GAG GTT ATA GG 3'
CCR-1 (F) 5' CCC AAT GGG AAT TCA CTC ACC A 3' 200
(P) 5' (FAM) CCT GCA GCC TTC ACT TTC CTC ACG AAA (TARMA) 3'
(R) 5' CAA ACG GAC AGC TTT GGA TT 3'
CCR-3 (F) 5' CAC AGC AGA GCC GGA ACT C 3' 75
(P) 5' (FAM) TGT GTT TTA GGT CAG ATG CAG AAA AT (TARMA) 3'
(R) 5' CTC CTT GGT CCT TCC TCT TTA GG 3'
CCR-5 (F) 5' ACT GCA AAA GGC TGA AGA GC 3' 204
(P) 5' (FAM) ACT GAC ATC TAC CTG CTC AAC CTG GCC A (TARMA) 3'
(R) 5' CGA TTG TCA GGA GGA TGA TG 3'
CCR-7 (F) 5' ACG GAC GAT TAC ATC GGA GA 3' 195
(P) 5' (FAM) ACA CGA CCA GCC CAT TGC CCA GT (TARMA) 3'
(R) 5' GGT CAT GGT CTT GAG CCT CT 3'
FasL (F) 5' ACC TCA AGG GGG ACT GTC TT 3' 170
(P) 5' (FAM) ACA TGG TTG TGA CCT GAG GAT TTA AGG GAT GG (TARMA) 3'
(R) 5' TTA GTT TCA CCG ATG GCT CA 3'
TRAIL (F) 5' CCC CTG CTG GCA AGT CAA 3' 68
(P) 5' (FAM) TGG CAA CTC CGT CAG CTC GTT (TARMA) 3'
(R) 5' CCT CAG AGG TTC TCA AAA TCA TCT T 3'
F, forward primers; R, reverse primers; P, Taqman probes
TLR, toll-like receptor; CCR, chemokine receptor; FasL, Fas ligand; TRAIL, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
BMC Immunology 2009, 10:35 http://www.biomedcentral.com/1471-2172/10/35recommendation. The cDNA synthesised were diluted
(1:50) and quantified by real-time PCR using Taqman
Technology (Applied Biosystems, CA, USA). Specific
primers (Table 2) were used and non-specific reactions
and primer-dimer artifacts have been minimised (as eval-
uated by gel electrophoresis). Detection of PCR product
was based on Taqman fluorescence signal. Standard
curves were generated using serial dilutions of plasmids
(~10 – 1010 copies) containing cloned sequences
involved. Results were calculated as the number of tar-
geted molecules/μL cDNA. To standardise results for vari-
ability in RNA and cDNA quantity and quality, we express
the results as the number of target copies per 104 copies of
β actin gene, which was determined previously [8].
Statistical analysis
All data were expressed as mean ± SEM. All samples were
paired and differences between groups were analyzed by
paired Student t test or the non-parametric equivalents
using the Instat software (GraphPad Software, Inc. San
Diego, CA, USA).
Abbreviations
SARS: severe acute respiratory syndrome; CoV: coronavi-
rus; DC: dendritic cell; CB: cord blood; FRhK-4 cells: fetal
rhesus kidney 4 cells; MOI: multiplicity of infection; TLR:
toll-like receptor; CCR: chemokine receptor; DRL: death
receptor ligand
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